BioElectronics Announces Results Of Menstrual Pain Pilot Clinical Study

Main Category: Women's Health / Gynecology
Also Included In: Pain / Anesthetics
Article Date: 04 Feb 2009 - 7:00 PDT

email to a friend   printer friendly   opinions  

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced results of a new pilot clinical study on use of the company's Allay™ product for the treatment of menstrual pain.

In a study conducted by Dr. Barry Eppley, 23 female patients (ages 19 to 37) with problematic menstrual issues used the Allay patch continuously for five days when the onset of their menstrual period was evident. The women rated their pain over this time frame using the same 1-10 pain scale that they had used during a control period. During the control period the average composite pain rating was 7.8 with average daily composite pain ratings from day one to five at 8.3, 7.9, 7.4, 6.5 and 5.7, respectively. During the Allay treatment sessions the average composite pain rating was only 5.4, with average daily composite pain ratings of 5.7, 4.8, 4.3, 3.4, and 2.1. This correlates to overall pain reduction on a daily basis of 31%, 39%, 42%, 48% and 73%, for these days respectively.

"Our findings that the Allay product offers a meaningful reduction in pain is not surprising to me as they are consistent with what I have observed in recovery after numerous plastic surgery procedures," commented Dr. Eppley. "The product appears to have a useful role for women who suffer from painful periods. Its effectiveness, ease-of-use and low cost make it an ideal therapeutic option for many women who experience moderate to severe menstrual pain and discomfort." http://www.drbarryeppley.com

About BioElectronics Corporation

BioElectronics Corporation is the maker of the Allay™ Menstrual Pain Therapy, the RecoveryRx™ Therapy, the HealFast™ Therapy for veterinary applications and ActiPatch® Therapy. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device, as have numerous other international record for agencies. http://www.bioelectronicscorp.com.

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

BioElectronics Corporation

• Additional
• References
• Citations